Literature DB >> 20118974

Surgical oncology: why biopsying metastatic breast cancer should be routine.

Anand Sharma, Tim Crook, Alastair Thompson, Carlo Palmieri.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20118974     DOI： 10.1038/nrclinonc.2009.222

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Clinical application of the 70-gene profile: the MINDACT trial.

Authors:  Fatima Cardoso; Laura Van't Veer; Emiel Rutgers; Sherene Loi; Stella Mook; Martine J Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

2.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

3.  Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

Authors:  Allan Lipton; Kim Leitzel; Suhail M Ali; Laurence Demers; Harold A Harvey; Hilary A Chaudri-Ross; Dean Evans; Raquel Lang; Wolfgang Hackl; Peter Hamer; Walter Carney
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

4.  [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].

Authors:  Bo Wang; Zhong-Zhen Guan; Dong-Geng Liu; Tong-Yu Lin; Li Zhang; Zhong-Jun Xia; Xiao-Yu Teng
Journal:  Ai Zheng       Date:  2004-12

5.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.

Authors:  Britta Weigelt; Zhiyuan Hu; Xiaping He; Chad Livasy; Lisa A Carey; Matthew G Ewend; Annuska M Glas; Charles M Perou; Laura J Van't Veer
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

6.  Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Authors:  C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2009-07-12       Impact factor: 32.976

7.  Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

Authors:  T Kuukasjärvi; J Kononen; H Helin; K Holli; J Isola
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

8.  Estrogen and progesterone receptor concordance between primary and recurrent breast cancer.

Authors:  B D Li; A Byskosh; A Molteni; R B Duda
Journal:  J Surg Oncol       Date:  1994-10       Impact factor: 3.454

Review 9.  Development of the 21-gene assay and its application in clinical practice and clinical trials.

Authors:  Joseph A Sparano; Soonmyung Paik
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

10.  Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

Authors:  C Simmons; N Miller; W Geddie; D Gianfelice; M Oldfield; G Dranitsaris; M J Clemons
Journal:  Ann Oncol       Date:  2009-03-18       Impact factor: 32.976
  10 in total
  6 in total

Review 1.  The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

Authors:  Mustafa Khasraw; Edi Brogi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

2.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

Authors:  Alastair M Thompson; Lee B Jordan; Philip Quinlan; Elizabeth Anderson; Anthony Skene; John A Dewar; Colin A Purdie
Journal:  Breast Cancer Res       Date:  2010-11-08       Impact factor: 6.466

3.  IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.

Authors:  Carlo Palmieri; Rob C Stein; Xinxue Liu; Emma Hudson; Hanna Nicholas; Hironobu Sasano; Fouzia Guestini; Chris Holcombe; Sophie Barrett; Laura Kenny; Sadie Reed; Adrian Lim; Larry Hayward; Sacha Howell; R Charles Coombes
Journal:  Breast Cancer Res Treat       Date:  2017-06-13       Impact factor: 4.872

Review 4.  Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance.

Authors:  Rupesh Kotecha; Raees Tonse; Muni Rubens; Michael W McDermott; Yazmin Odia; Haley Appel; Minesh P Mehta
Journal:  Neurooncol Adv       Date:  2021-01-16

5.  Early diagnosis of breast cancer lung metastasis by nanoprobe-based luminescence imaging of the pre-metastatic niche.

Authors:  Hanwen Zheng; Chunsen Yuan; Jiajun Cai; Wendan Pu; Peng Wu; Chenwen Li; Gang Li; Yang Zhang; Jianxiang Zhang; Jiawei Guo; Dingde Huang
Journal:  J Nanobiotechnology       Date:  2022-03-15       Impact factor: 10.435

6.  Cancer epigenetics: new therapies and new challenges.

Authors:  Eleftheria Hatzimichael; Tim Crook
Journal:  J Drug Deliv       Date:  2013-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.